Ikena Oncology Inc (IKNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ikena Oncology Inc (IKNA) has a cash flow conversion efficiency ratio of -0.030x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.42 Million) by net assets ($115.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Ikena Oncology Inc to measure how many days the company can operate on defensive assets alone.
Ikena Oncology Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Ikena Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ikena Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ikena Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pansar Bhd
KLSE:8419
|
0.249x |
|
LLORENTE + CUENCA EO -01
F:91P
|
N/A |
|
Lixte Biotechnology Holdings Inc
NASDAQ:LIXT
|
-0.099x |
|
JKG Land Bhd
KLSE:6769
|
0.154x |
|
TEAM INC. DL-30
F:T9CA
|
-0.685x |
|
Arovella Therapeutics Ltd
AU:ALA
|
-0.090x |
|
Korfez Gayrimenkul Yatirim
IS:KRGYO
|
0.084x |
|
Cimbeton Hazirbeton ve Prefabrik Yapi Elemanlari Sanayi ve Ticaret AS
IS:CMBTN
|
0.316x |
Annual Cash Flow Conversion Efficiency for Ikena Oncology Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Ikena Oncology Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Ikena Oncology Inc (IKNA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $125.93 Million | $-46.00 Million | -0.365x | +22.23% |
| 2023-12-31 | $169.76 Million | $-79.74 Million | -0.470x | +6.84% |
| 2022-12-31 | $146.97 Million | $-74.11 Million | -0.504x | -73.97% |
| 2021-12-31 | $207.88 Million | $-60.25 Million | -0.290x | -177.43% |
| 2020-12-31 | $-101.05 Million | $-37.83 Million | 0.374x | +148.01% |
| 2019-12-31 | $-61.46 Million | $47.93 Million | -0.780x | -407.93% |
| 2018-12-31 | $-45.84 Million | $-11.61 Million | 0.253x | -- |
About Ikena Oncology Inc
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by… Read more